1-(3-bromo-phenyl)-1H-[1,2,4]-triazole-3-carboxylic acid | 1443758-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-bromo-phenyl)-1H-[1,2,4]-triazole-3-carboxylic acid
• 英文别名: 1-(3-bromophenyl)-1,2,4-triazole-3-carboxylic acid
• CAS: 1443758-90-4
• 化学式: C₉H₆BrN₃O₂
• 分子量: 268.07
• InChiKey: FXRAENLSDRQSRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-bromo-phenyl)-1H-[1,2,4]-triazole-3-carboxylic acid 在 titanium(IV) isopropylate 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 氯化亚砜 、 caesium carbonate 、 三乙胺 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 甲苯 为溶剂， 反应 37.75h， 生成 1-(1-(3-cyclopropylphenyl)-1H-[1,2,4]-triazol-3-yl)cyclopropylamine
  参考文献：
  名称：

  ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER

  摘要：

  公开号：

  EP3434674B1
• 作为产物：
  描述：

  Ethyl 1-(3-bromophenyl)-1,2,4-triazole-3-carboxylate 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以98.2%的产率得到1-(3-bromo-phenyl)-1H-[1,2,4]-triazole-3-carboxylic acid
  参考文献：
  名称：

  ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER

  摘要：

  公开号：

  EP3434674B1

文献信息

• [EN] PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE ET LEUR UTILISATION À TITRE DE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR5
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013087805A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

  这项发明涉及公式(I)化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1、R2、R3、R4、Q在描述中有给定的含义。
• NOVEL COMPOUNDS
  申请人：HEIMANN Annekatrin

  公开号：US20130158042A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R 1 , R 2 , R 3 , R 4 , Q have meanings given in the description.

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1，R2，R3，R4，Q在描述中给出了含义。
• Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
  申请人：Heimann Annekatrin

  公开号：US08883789B2

  公开（公告）日：2014-11-11

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

  本发明涉及公式I的化合物，它们用作mGlu5受体活性的正向变构调节剂，含有它们的制药组合物，以及将它们用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知衰退，如痴呆或认知损害的药物的方法。 R1，R2，R3，R4，Q在描述中给出其含义。
• COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Haihe Pharmaceutical Co., Ltd.

  公开号：EP3434674A1

  公开（公告）日：2019-01-30

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。
• Compound having mutant IDH inhibitory activity, preparation method and use thereof
  申请人：SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.

  公开号：US10682352B2

  公开（公告）日：2020-06-16

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。